Pipeline

 

Zyngenia has applied its technology to generate a pipeline that is comprised of innovative multi-specific and multi-valent biotherapeutics (Zybodies™) that address well-validated targets. Zyngenia has advanced three programs into preclinical development and achieved preclinical proof-of-concept with both bi-specific and tri-specific Zybodies in cancer and inflammation.

 

Zybody MOA

Targent product Population

Discovery

Development Stage

Preclinical

Clinical

Antibody

Scaffold MRD Specificities

ONCOLOGY PROGRAMS

Enhanced cytotoxicity and/or inhibition of disease - promoting

Head & Neck Cancer, NSCLC

 

mAb:Cetuximab

MRD: anti-Her3

mAb: Cetuximab

MRD:anti-Her3 anti-Her1

 

Colorectal,

NSCLC, Head & Neck Cancer

 

 

Advance one

product to IND

 in 1H2020

 

 

 

Enhanced receptor internalization

Metastatic breast Cancer

 

mAb:Trastuzumab

MRD: anti-Her2

(Drug conjugate)

Early-stage

partnership

opportunities

 

 

Agonistic receptor signaling

Multiple Myeloma

 

mAb:DR5,CS, or CD33

MRD:anti-DR5

 

Early-stage

partnership

opportunities

 

 

 

INFLAMMATION PROGRAMS

Enhanced clearance of multiple cytokines

Rheumatoid Arthritis & Inflammatory Disease

 

mAb:Adalimumab

MRD:anti-Ang-2

 

IND Application

1H2019

 

 

 

Contact

Site Map

Terms & Conditions

© 2017 Zyngenia